HEALIOS K.K. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 161 JPY | -2.42% |
|
+1.90% | -2.42% |
| Jun. 06 | Healios Enters Alliance, Bond Purchase Deal with Alfresa | MT |
| Apr. 10 | Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen | MT |
| Sales 2024 * | 300M 1.91M | Sales 2025 * | 1.47B 9.36M | Capitalization | 14.51B 92.52M |
|---|---|---|---|---|---|
| Net income 2024 * | -3.29B -20.97M | Net income 2025 * | -2.31B -14.71M | EV / Sales 2024 * | 45.6 x |
| Net cash position 2024 * | 822M 5.24M | Net Debt 2025 * | 608M 3.88M | EV / Sales 2025 * | 10.3 x |
| P/E ratio 2024 * |
-4.04
x | P/E ratio 2025 * |
-5.66
x | Employees | 64 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.42% | ||
| 1 week | +1.90% | ||
| Current month | +1.90% | ||
| 1 month | +1.26% | ||
| 3 months | +17.52% | ||
| 6 months | -6.94% | ||
| Current year | -2.42% |
1 week
155.00
184.00
1 month
125.00184.00
Current year
114.00189.00
1 year
114.00332.00
3 years
114.002 557.00
5 years
114.002 557.00
10 years
114.002 669.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hardy Kagimoto
CEO | Chief Executive Officer | 47 | 11-02-23 |
Richard Kincaid
DFI | Director of Finance/CFO | 47 | 18-02-28 |
Masanori Sawada
CTO | Chief Tech/Sci/R&D Officer | 42 | 12-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 12-12-31 | |
| Director/Board Member | 72 | 18-02-28 | |
Hardy Kagimoto
CEO | Chief Executive Officer | 47 | 11-02-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 161 | -2.42% | 1,770,100 |
| 24-06-06 | 165 | +3.12% | 5,543,600 |
| 24-06-05 | 160 | -3.61% | 1,093,000 |
| 24-06-04 | 166 | +4.40% | 1,245,500 |
| 24-06-03 | 159 | +0.63% | 2,703,600 |
Delayed Quote Japan Exchange, June 07, 2024 at 02:00 am EDT
More quotes
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
161
JPY
Average target price
280
JPY
Spread / Average Target
+73.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.42% | 92.67M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- 4593 Stock
